About: Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch
Creator	Baldo, Brian Pham, Nghia
source	PMC
abstract	More than 100 drugs are used to treat the many different cancers. They can be divided into agents with relatively broad, non-targeted specificity and targeted drugs developed on the basis of a more refined understanding of individual cancers and directed at specific molecular targets on different cancer cells. Individual drugs in both groups have been classified on the basis of their mechanism of action in killing cancer cells. The targeted drugs include proteasome inhibitors, toxic chimeric proteins and signal transduction inhibitors such as tyrosine kinase (non-receptor and receptor), serine/threonine kinase, histone deacetylase and mammalian target of rapamycin inhibitors. Increasingly used targeted vascular (VEGF) and platelet-derived endothelial growth factor blockade can provoke a range of pathological consequences. Many of the non-targeted drugs are cytotoxic, suppressing haematopoiesis as well as provoking cutaneous eruptions and vascular, lung and liver injury. Cytotoxic side effects of the targeted drugs occur less often and usually with less severity, but they show their own unusual adverse effects including, for example, a lengthened QT interval, a characteristic papulopustular rash, nail disorders and a hand–foot skin reaction variant. The term hypersensitivity is widely used across a number of disciplines but not always with the same definition in mind, and the terminology needs to be standardised. This is particularly apparent in cancer chemotherapy where anti-neoplastic drug-induced thrombocytopenia, neutropenia, anaemia, vascular disorders, liver injury and lung disease as well as many dermatological manifestations sometimes have an immune basis. The most insidious of all adverse consequences of targeted therapies, however, are tumour adaptation, increased malignancy and the invasive metastatic switch seen with anti-angiogenic drugs that inhibit the VEGF-A pathway. Adverse reactions to 44 non-targeted and 33 targeted, frequently used, chemotherapeutic drugs are presented together with discussions of diagnosis, premedications, desensitizations and importance of understanding the mechanisms underlying the various drug-induced reactions. There is need for wide-ranging acceptance of what constitutes a hypersensitivity reaction and for allergists to be more involved in the diagnosis, treatment and prevention of chemotherapeutic drug-induced hypersensitivity reactions.
has issue date	2013-09-17(xsd:dateTime)
bibo:doi	10.1007/s10555-013-9447-3
bibo:pmid	24043487
has license	no-cc
sha1sum (hex)	01a203b05c7c97bd6716617b5f9ffb8cd7b9e18d
schema:url	https://doi.org/10.1007/s10555-013-9447-3
resource representing a document's title	Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch
has PubMed Central identifier	PMC7102343
has PubMed identifier	24043487
schema:publication	Cancer Metastasis Rev
resource representing a document's body	covid:01a203b05c7c97bd6716617b5f9ffb8cd7b9e18d#body_text
is schema:about of	named entity 'frequently' named entity 'Cytotoxic' named entity 'groups' named entity 'diagnosis' named entity 'target' named entity 'inhibitors' named entity 'Adverse' named entity 'switch' named entity 'provoke' named entity 'disciplines' named entity 'This' named entity 'drug-induced' named entity 'drugs' named entity 'drugs' named entity 'hypersensitivity reaction' named entity 'apparent' named entity 'cytotoxic' named entity 'drugs' named entity 'Many' named entity 'pathological' named entity 'classified' named entity 'injury' named entity 'inhibit' named entity 'haematopoiesis' named entity 'rapamycin' named entity 'prevention' named entity 'thrombocytopenia' named entity 'reactions' named entity 'metastatic' named entity 'adverse effects' named entity 'hypersensitivity' named entity 'lung disease' named entity 'hypersensitivity reactions' named entity 'haematopoiesis' named entity 'anaemia' named entity 'proteasome inhibitors' named entity 'cutaneous' named entity 'Adverse reactions' named entity 'desensitizations' named entity 'VEGF-A' named entity 'hypersensitivity reaction' named entity 'tyrosine kinase' named entity 'chemotherapeutic drugs' named entity 'cytotoxic' named entity 'dermatological' named entity 'tyrosine kinase' named entity 'targeted' named entity 'autoimmunity' named entity 'FGFR2' named entity 'chemotherapy' named entity 'fulminant' named entity 'phenylalanine' named entity 'asparaginase' named entity 'maculopapular' named entity 'angiogenesis' named entity 'anti-neoplastic' named entity 'rash' named entity 'taxanes' named entity 'palmar-plantar erythrodysesthesia' named entity 'nitrogen mustards' named entity 'acute lymphoblastic leukemia' named entity 'neutrophils' named entity 'fever' named entity 'c-Met' named entity 'FLT3' named entity 'Proto-oncogene' named entity 'humoral' named entity 'cancer cells' named entity 'hormone' named entity 'apoptosis' named entity 'eosinophilia' named entity 'mTOR inhibitor' named entity 'neutrophil' named entity 'hyperpigmentation' named entity 'jaundice' named entity 'cough' named entity 'anaemia' named entity 'antimetabolites' named entity 'acute hepatitis' named entity 'active metabolite'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software